tldrdailynews.com logo

Infinimmune lands $75M Series A to push eczema antibodies forward

1 min read
Source: Fierce Biotech
Infinimmune lands $75M Series A to push eczema antibodies forward
Photo: Fierce Biotech
TL;DR

Biotech startup Infinimmune raises $75 million in a Series A led by Regeneron Ventures (with Playground Global) to advance its human B cell–based antibody platform for eczema, including lead antibodies IFX-201 and IFX-101 moving to Phase 1 next year. Regeneron’s investment aims to complement Dupixent, Merck remains an investor, and the company envisions additional large‑pharma partnerships as it advances its pipeline.

Topics:businessbiotech#antibodies#biotech#eczema#infinimmune#regeneron-ventures#series-a
Share this article
  1. Regeneron backs $75M series A for antibody upstart Infinimmune  Fierce Biotech
  2. Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M  Endpoints News
  3. Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease  Business Wire
  4. Re-engineering immune memory for tissue repair  Longevity.Technology
  5. Chasing Dupixent, a biotech aims to make better antibody drugs for eczema  BioPharma Dive

Want the full story? Read the original reporting

Read on Fierce Biotech